<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00587769</url>
  </required_header>
  <id_info>
    <org_study_id>07-003998</org_study_id>
    <nct_id>NCT00587769</nct_id>
  </id_info>
  <brief_title>Chantix &amp; Bupropion for Smoking Cessation</brief_title>
  <acronym>ChanBan</acronym>
  <official_title>Combination Pharmacotherapy With Chantix &amp; Bupropion for Smoking Cessation (ChanBan)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overarching goal of this line of research is to increase smoking abstinence rates using a
      combination of existing pharmacotherapies. The aim of the current study is to assess the
      safety and compliance as well as obtain preliminary estimates of efficacy and effect on
      craving and nicotine withdrawal of combination therapy with bupropion SR and varenicline. We
      will compare the efficacy estimates in this study with historical smoking abstinence rates
      with varenicline. To accomplish our aims, we will enroll 38 cigarette smokers in an
      open-label, phase II clinical trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will be eligible to participate if they: 1) are at least 18 years of age; 2) have
      smoked 10 or more cigarettes per day for at least 6 months; and 3) are motivated to stop
      smoking.

      Subjects will be excluded if they have: 1) an unstable medical condition; 2) unstable angina,
      myocardial infarction, or coronary angioplasty within the past 3 months or an untreated
      cardiac dysrhythmia; 3) personal history of seizures; 4) closed head trauma with any loss of
      consciousness or amnesia in the last 5 years; 5) ever history of closed head trauma with &gt; 30
      minutes of loss of consciousness or amnesia or resulting in skull fracture or subdural
      hematoma/brain contusion; 6) a history or psychosis, bipolar disorder, bulimia or anorexia
      nervosa); 7) have current depression as assessed by Center for Epidemiologic Studies
      Depression (CES-D); 8) have active substance abuse other than nicotine; 9) have used an
      investigational drug within the last 30 days; 10) are currently using a behavioral or
      pharmacologic tobacco treatment and unwilling or unable to discontinue use; 11) use of
      bupropion or varenicline in the previous 3 months; 12) current (past 14 days) use of
      antipsychotic or antidepressant; 13) an allergy to bupropion or varenicline; 14) untreated
      hypertension or baseline systolic blood pressure &gt; 180 or diastolic &gt; 100; 15) have another
      member of their household already participating in this study.

      The primary aims and hypotheses of this study are:

        1. To obtain preliminary evidence of efficacy of 12 weeks of combination therapy with
           bupropion SR and varenicline for increasing the point prevalence smoking abstinence
           rates at 12 weeks among cigarette smokers.

           Hypothesis: The combination of bupropion SR plus varenicline for 12 weeks will increase
           the point prevalence smoking abstinence rates at 12 weeks among cigarettes smokers.

        2. To obtain preliminary evidence of efficacy of combination therapy with bupropion SR and
           varenicline for decreasing craving and nicotine withdrawal symptoms among cigarette
           smokers trying to achieve smoking abstinence.

      Hypothesis: 12 weeks of combination therapy with bupropion SR and varenicline will
      significantly decrease craving and nicotine withdrawal among cigarette smokers trying to
      achieve smoking abstinence.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Point Prevalence Smoking Abstinence at 12 Weeks: the Number of Patients Who Refrained From Smoking at 12 Weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>Smoking abstinence biochemically confirmed with exhaled carbon monoxide concentrations</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Point Prevalence Smoking Abstinence at 6 Months: the Number of Patients Who Refrained From Smoking at 6 Months</measure>
    <time_frame>6 months</time_frame>
    <description>Smoking abstinence biochemically confirmed with exhaled carbon monoxide concentrations</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Smoking</condition>
  <condition>Tobacco Use Disorder</condition>
  <arm_group>
    <arm_group_label>Bupropion SR &amp; Varenicline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All 38 smokers will receive open-label bupropion SR and varenicline. Bupropion SR is an oral medication with recommended dosing of 150 mg by mouth once day for 3 days then 150 mg by mouth twice per day. Varenicline is an oral medication with recommended dosing of 0.5 mg once daily for 3 days, increasing to 0.5 mg twice daily for days 4 to 7, and then to the maintenance dose of 1 mg twice daily for the 12 weeks of treatment. Subjects will quit on Day #8 after starting both medications.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupropion SR &amp; Varenicline</intervention_name>
    <description>Bupropion SR 150 mg by mouth once day for 3 days then 150 mg by mouth twice per day.
Varenicline 0.5 mg once daily for 3 days, increasing to 0.5 mg twice daily for days 4 to 7, and then to the maintenance dose of 1 mg twice daily for the 12 weeks of treatment.</description>
    <arm_group_label>Bupropion SR &amp; Varenicline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  at least 18 years of age

          -  have smoked 10 or more cigarettes per day for at least 6 months

          -  are motivated to stop smoking.

        Exclusion Criteria:

          -  an unstable medical condition

          -  unstable angina, myocardial infarction, or coronary angioplasty within the past 3
             months or an untreated cardiac dysrhythmia

          -  personal history of seizures

          -  closed head trauma with any loss of consciousness or amnesia in the last 5 years

          -  ever history of closed head trauma with &gt; 30 minutes of loss of consciousness or
             amnesia or resulting in skull fracture or subdural hematoma/brain contusion

          -  a history or psychosis, bipolar disorder, bulimia or anorexia nervosa)

          -  have current depression as assessed by Center for Epidemiologic Studies Depression
             (CES-D)

          -  have active substance abuse other than nicotine

          -  have used an investigational drug within the last 30 days

          -  are currently using a behavioral or pharmacologic tobacco treatment and unwilling or
             unable to discontinue use

          -  use of bupropion or varenicline in the previous 3 months

          -  current (past 14 days) use of antipsychotic or antidepressant

          -  an allergy to bupropion or varenicline

          -  untreated hypertension or baseline systolic blood pressure &gt; 180 or diastolic &gt; 100

          -  have another member of their household already participating in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jon O Ebbert, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://ndc.mayo.edu/mayo/research/nicotine_research_center/</url>
    <description>Mayo Clinic Nicotine Research Program</description>
  </link>
  <link>
    <url>http://clinicaltrials.mayo.edu</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 21, 2007</study_first_submitted>
  <study_first_submitted_qc>December 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2008</study_first_posted>
  <results_first_submitted>October 5, 2010</results_first_submitted>
  <results_first_submitted_qc>November 29, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 23, 2010</results_first_posted>
  <last_update_submitted>April 16, 2013</last_update_submitted>
  <last_update_submitted_qc>April 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 24, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Jon Ebbert</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Smoking</keyword>
  <keyword>Smoking cessation</keyword>
  <keyword>Bupropion</keyword>
  <keyword>Varenicline</keyword>
  <keyword>Tobacco use disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Varenicline</mesh_term>
    <mesh_term>Bupropion</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patient's were recruited between 10 September, 2007 and 25 October, 2007 in the community surrounding the Mayo Clinic in Rochester Minnesota.</recruitment_details>
      <pre_assignment_details>Patients were excluded for not meeting entry criteria</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Medication Arm</title>
          <description>Varenicline 1.0 mg po bid plus bupropion 150 mg po bid</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Medication Arm</title>
          <description>Varenicline 1.0 mg po bid plus bupropion 150 mg po bid</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="38"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.1" spread="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cigarettes per day</title>
          <units>cigarettes per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.9" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Point Prevalence Smoking Abstinence at 12 Weeks: the Number of Patients Who Refrained From Smoking at 12 Weeks</title>
        <description>Smoking abstinence biochemically confirmed with exhaled carbon monoxide concentrations</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Medication Arm</title>
            <description>Varenicline 1.0 mg po bid plus bupropion 150 mg po bid</description>
          </group>
        </group_list>
        <measure>
          <title>Point Prevalence Smoking Abstinence at 12 Weeks: the Number of Patients Who Refrained From Smoking at 12 Weeks</title>
          <description>Smoking abstinence biochemically confirmed with exhaled carbon monoxide concentrations</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27" lower_limit="54" upper_limit="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Point Prevalence Smoking Abstinence at 6 Months: the Number of Patients Who Refrained From Smoking at 6 Months</title>
        <description>Smoking abstinence biochemically confirmed with exhaled carbon monoxide concentrations</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Medication Arm</title>
            <description>Varenicline 1.0 mg po bid plus bupropion 150 mg po bid</description>
          </group>
        </group_list>
        <measure>
          <title>Point Prevalence Smoking Abstinence at 6 Months: the Number of Patients Who Refrained From Smoking at 6 Months</title>
          <description>Smoking abstinence biochemically confirmed with exhaled carbon monoxide concentrations</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Medication Arm</title>
          <description>Varenicline 1.0 mg po bid plus bupropion 150 mg po bid</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Sleep disturbance</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Vivid dreams</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jon O. Ebbert</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>507-284-2511</phone>
      <email>ebbert.jon@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

